Abbott Laboratories, ABT and earnings per share

Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session,
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks Consensus Estimate. However, the figure improved 12.6% from the prior-year quarter’s level.
Abbott’s (ABT) Impressive Q4 and Bold Projections for 2025: What You Need to Know
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 and $1.09, further underscoring its momentum heading into the new year.
Abbott Laboratories (ABT) Projected to Post Earnings on Wednesday
Abbott Laboratories (NYSE:ABT – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, January 22nd. Analysts expect Abbott Laboratories to post earnings of $1.
Abbott Laboratories (NYSE:ABT) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 22, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.34 EPS, expectations were $1.34. Operator: Good morning and thank you for standing by.
Abbott Laboratories Q4 Profit Increases, Inline With Estimates
Abbott Laboratories (ABT) revealed a profit for its fourth quarter that increased from last year in line with the Street estimates.
Abbott (ABT) Q4 Earnings Meet Estimates
Abbott (ABT) came out with quarterly earnings of $1.34 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.19 per share a year ago. These figures are adjusted for non-recurring items.
RBC Capital Sticks to Its Buy Rating for Abbott Laboratories (ABT)
In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), ...
bovnews1d
Why Abbott Laboratories (ABT) Stock is Currently 2.73% Above from Its 20-Day SMA?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.66% of ...
Yahoo Finance4d
Jim Cramer on Abbott Laboratories (ABT): ‘I Think Abbott Will Win These Baby Formula Cases’
In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other stocks on Jim Cramer's radar. Jim Cramer, host of Mad Money, recently emphasized the ...
Mizuho Securities Reaffirms Their Hold Rating on Abbott Laboratories (ABT)
Mizuho Securities analyst Anthony Petrone maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday. The company’s ...
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
Royal Bank of Canada Reiterates “Outperform” Rating for Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (NYSE:ABT – Get Free Report)‘s stock had its “outperform” rating reissued by equities researchers at Royal Bank of Canada in a report issued on Tuesday,Benzinga reports. They ...
MassDevice1d
Abbott sales come up just shy of Q4 expectations on Wall Street, highlights EP growth
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Abbott Laboratories’ Growth Prospects and Market Leadership in MedTech Justify Buy Rating
BTIG analyst Marie Thibault maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...